Dr. Hammers on the CheckMate-214 Study for RCC

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).

CheckMate-214 is a large phase III trial that randomized 1000 patients to nivolumab (Opdivo) plus ipilimumab (Yervoy) or sunitinib (Sutent). The primary analysis was focused on the intermediate- and poor-risk patients, explains Hammers.

A median progression-free survival (PFS) was a challenge to achieve, but according to Hammers, the combination will become the new standard of care.